A crossover study on lipid and weight changes associated with olanzapine and risperidone

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Psychopharmacology

• Publication date

  2005-10-21

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00213-005-0205-2PMID 16240162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risperidone alternative for a schizophrenic patient with olanzapine‐exacerbated diabetic mellitus

  2006cited by this paper
• Atypical antipsychotic therapy and hyperlipidemia: a review.

  2005cited by this paper
• Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism

  2004cited by this paper
• The effects of antipsychotic therapy on serum lipids: a comprehensive review.

  2004cited by this paper
• Guidelines for computer modeling of diabetes and its complications

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.

  2004cited by this paper
• A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol.

  2003cited by this paper
• Weight Change after an Atypical Antipsychotic Switch

  2003cited by this paper
• Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

  2003cited by this paper
• A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.

  2002cited by this paper
• The effects of novel antipsychotics on glucose and lipid levels.

  2002cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

  2002cited by this paper
• The Merck index : an encyclopedia of chemicals, drugs, and biologicals

  2001cited by this paper
• Lipid abnormalities induced by novel antipsychotic drugs.

  2001cited by this paper
• Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities

  2001cited by this paper
• Lipid Abnormalities Induced by Novel Antipsychotic Drugs

  2001cited by this paper
• Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

  2000cited by this paper
• Recent advances in basic obesity research.

  1999cited by this paper
• Elevated Serum Triglycerides with Clozapine Resolved with Risperidone in Four Patients

  1999cited by this paper
• Olanzapine increases weight and serum triglyceride levels.

  1999cited by this paper
• An evaluation of various indices of body weight change and their relationship with coronary risk factors.

  1996cited by this paper
• Human obesity: from lipid abnormalities to lipid oxidation.

  1995cited by this paper
• Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

  1986cited by this paper
• The triglyceride issue: a view from Framingham.

  1986cited by this paper
• Abnormal histidine metabolism in thyrotoxicosis in man. A possible index of impaired folate function.

  1965cited by this paper

• A Comparative Follow-up Study of Metabolic Syndrome in Schizophrenia Patients Treated with Olanzapine and Risperidone

  2026cites this paper
• Association of Disease Duration and Duration of Olanzapine Use with Blood Sugar, Blood Pressure, BMI, and Lipid Profile among Schizophrenic Patients in Iraq

  2023cites this paper
• Ultrastructure and Pathology Study of the Effect of an Antidepressant (Olanzapine) on the Health of Mitochondria in liver of male Albino Rat

  2020cites this paper
• The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.

  2020cites this paper
• Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review

  2014cites this paper
• Paliperidone Extended-Release: Safety and Tolerability from a Metabolic Profile Perspective

  2013cites this paper
• Atypical Antipsychotic Drugs, Schizophrenia, and Metabolic Syndrome in Non–Euro-American Societies

  2012cites this paper
• Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable

  2012cites this paper
• Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.

  2012cites this paper
• Excessive insulin secretion in Japanese schizophrenic patients treated with antipsychotics despite normal fasting glucose levels.

  2012influential citation
• Metabolic Adverse Effects Associated with Antipsychotic Medications

  2011cites this paper
• Risperidone versus other atypical antipsychotics for schizophrenia.

  2011cites this paper
• The Role of High-Density Lipoprotein Cholesterol in the Development of Atherosclerotic Cardiovascular Disease

  2011cites this paper
• Olanzapine versus other atypical antipsychotics for schizophrenia.

  2010cites this paper
• Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.

  2010cites this paper
• A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.

  2010cites this paper
• Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.

  2010cites this paper
• Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report

  2010cites this paper
• Orally disintegrating and standard olanzapine tablets similarly elevate the HOMA insulin resistance index and plasma triglyceride levels in healthy men

  2010cites this paper
• Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

  2009cites this paper
• Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.

  2009cites this paper
• Adverse Endocrine and Metabolic Effects of Psychotropic Drugs

  2009cites this paper
• Strategies for dosing and switching antipsychotics for optimal clinical management.

  2008cites this paper
• Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

  2008cites this paper
• eview linical monitoring and management of the metabolic yndrome in patients receiving atypical antipsychotic edications

  2008cites this paper
• Red Yeast Rice for a patient with olanzapine-induced dyslipidemia: a test-and-retest case report.

  2008cites this paper
• PSYCHIATRIC MEDICATIONS AND METABOLIC SYNDROME

  2008cites this paper
• Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.

  2008cites this paper
• A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.

  2007cites this paper
• Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.

  2007cites this paper
• Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.

  2007cites this paper
• Aripiprazole and worsening of psychosis: a case report.

  2007cites this paper
• Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.

  2007cites this paper
• Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.

  2007cites this paper
• A case report of reemergence of antipsychotic-induced dyskinesia with citalopram.

  2007cites this paper
• What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics?

  2007cites this paper
• Augmentation of clozapine treatment with aripiprazole.

  2007cites this paper
• Resolution of late-onset hypomania after repair of carotid artery stenosis: a case of vascular hypomania.

  2007cites this paper
• What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics?

  2007cites this paper
• Antipsychotic Medication–Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease

  2007cites this paper
• How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting

  2007cites this paper
• Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reas

  2007cites this paper
• Current awareness in human psychopharmacology

  2006cites this paper
• Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.

  2006cites this paper
• Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other

  2006cites this paper
• Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia

  2006cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2006cites this paper
• Internet assessment of obsessive-compulsive disorder.

  2006cites this paper
• A crossover study of prolactin changes associated with risperidone and olanzapine.

  2006cites this paper
• The Metabolic Effects of Antipsychotic Medications

  2006cites this paper